Health Discovery Corporation operates as a pattern recognition company that uses mathematical techniques to analyze large amounts of data to uncover patterns in the United States. The company’s principal intellectual property includes Support Vector Machines and Fractal Genomic Modeling, as well as biomarkers. Its technologies and discoveries comprise a subset of genes that separates benign prostatic hyperplasia (BPH) from prostate cancer and BPH from normal tissue patterns.
As of recent, HDC has made a buzz with rumors that they may have a new and more effective way of recognizing prostate cancer. They are partnered with Abbot, Quest, and even Pfizer. If they use HDC's biomarker recognition in any commercialization of a product, they will receive 30% of royalties. This is a buy and hold, for the gains could be monumental if the rumors are true.
No comments:
Post a Comment